A Multicenter Study Evaluating Efficacy and Safety of 177Lu-DOTA-TATE Based on Kidney-Dosimetry in Patients With Disseminated Neuroendocrine Tumors
NCT01456078
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
60
Enrollment
OTHER
Sponsor class
Conditions
Neuroendocrine Tumors
Liver Metastases
Interventions
DRUG:
177Lu-DOTA-TATE
Sponsor
Lund University Hospital